The new drugs advent: Clinical or economic outcomes?

Annals of Oncology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  De Maio, E ^a   Perrone, F ^a   Bisagni, G ^b   Boni, C ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Azienda Ospedaliera Arcisp S M   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; NEW DRUG; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MONOTHERAPY; MORBIDITY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; SURVIVAL ANALYSIS;

EID: 33645830721     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj934     Document Type: Article

References (20)

1. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
2. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149-2158.
3. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004; 22; 777-784.
4. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-794.
5. Gatzemeier U, Pluzanska A, Szczesna A et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23: 617 (abstr. 7010).
6. Herbst RS, Prager D, Hermann R et al. TRIBUTE - A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2005; 23(25): 5892-5899.
7. Chang S, Long SR, Kutikova L et al. Estimating the cost of cancer: result on the basis of claims data anlysis for cancer patients diagnosed with seven type of cancer during 1999 to 2000. J Clin Oncol 2004; 22 (17): 3524-3530.
8. Schrag D. The price tag on progress - Chemotherapy for colorectal cancer. N Engl J Medicine 2004; 351: 317-319.
9. Drummond MF, Davies L: Economic analysis alongside clinical trials: Revisiting the methodologies issues. Intl J Tech Assess Health Care 1991; 7: 561-563.
10. Drummond MF, Stoddart GL: Economic analysis and clinical trial. Controlled Clin Trials 1984; 5: 115-128.
11. Drummond M, Brandt A, Luce B, et al: Standardizing methodologies for economic evaluation in health care. Int J Tech Assess 1993; 9: 26-36.
12. Detsky AS: Guidelines for economic analysis of pharmaceutical products: A draft document for Ontario and Canada. Pharmacoeconomics 1993; 3: 354-361.
13. Henry D: Economic analysis as an aid to subsidization decisions: The development of Australian guidelines for pharmaceuticals. Pharmacoeconomics 1992; 2: 54-67.
14. Hill S, Mitchell S, Henry D. Problems with the interpretation of pharmacoeconomic analyses. JAMA 2000; 283(16): 2116-2121.
15. Messori A, Trippoli S, D'Alessandro A et al. Problems in pharmacoeconomic analyses, JAMA 2000; 284(15): 1992-1923.
16. Friedberg M, Saffran B, Stinson TJ et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999; 282(15): 1453-1457.
17. Weinstein MC, Siegel JE, Gold MR et al. Recommendations of the Panel on cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253-1258.
18. Rennie D. Pharmacoeconomic analyses. Making them transparent, making them credible. JAMA 2000; 283 (16): 2158-2160.
19. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of Oncology drugs. J Clin Oncol 2003; 21 (7): 1404-1411.
20. Carin A Uly-de Groot and Giaccone G. Health economics: Can we afford an unrestricted use of new biological agents in gastrointestinal oncology? Current Opinion in Oncology 2005; 17: 392-396.